Detalhe da pesquisa
1.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
N Engl J Med
; 389(22): 2063-2075, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861218
2.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658005
3.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial.
Lancet
; 401(10378): 733-746, 2023 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36764316
4.
Acquired Resistance to KRASG12C Inhibition in Cancer.
N Engl J Med
; 384(25): 2382-2393, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161704
5.
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.
Br J Cancer
; 128(10): 1906-1915, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871042
6.
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
Oncologist
; 28(7): 640-e559, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129455
7.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Lancet Oncol
; 23(6): 781-792, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35576957
8.
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.
Future Oncol
; 18(28): 3133-3141, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950566
9.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med
; 379(23): 2220-2229, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280641
10.
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 379(4): 341-351, 2018 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29863979
11.
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need.
Future Oncol
; 17(11): 1401-1439, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33475012
12.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Lancet Oncol
; 18(1): 42-51, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932068
13.
Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.
Oncologist
; 20(3): 299-306, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25660158
14.
The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
Cancer
; 120(24): 3853-8, 2014 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25155290
15.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Nat Med
; 30(3): 716-729, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38351187
16.
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
Nat Med
; 30(4): 1013-1022, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538867
17.
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Cancer
; 119(2): 356-62, 2013 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22810899
18.
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.
Clin Lung Cancer
; 24(3): 218-227, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36890020
19.
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
J Hematol Oncol
; 16(1): 66, 2023 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355629
20.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
J Clin Oncol
; 41(6): 1213-1227, 2023 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36327426